ProCE Banner Activity

RuxoBEAT: Interim Results From a Randomized Phase IIb Study of Ruxolitinib Vs BAT as First-line Therapy in High-Risk Polycythemia Vera

Conference Coverage

The first interim analysis of the ongoing phase IIb RuxoBEAT study found that ruxolitinib was not superior to best available therapy for complete response but saw increased reduction in spleen size and less patient-reported pruritus with ruxolitinib vs best available therapy for untreated polycythemia vera.

Released: December 13, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.